Health Care·Biotechnology·$5.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.63 | N/A | -28.57% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.63 | N/A | -28.57% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance due to ongoing market conditions. They emphasized their commitment to R&D despite the lack of specific guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on continuing its research and development efforts.
Celcuity Inc's earnings report indicates challenges in meeting expectations, particularly with a larger-than-expected loss per share. The stock's slight decline of 0.5% reflects investor concerns about the company's future performance and lack of guidance. Without clear direction, investors may remain cautious in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TAKE-TWO INTERACTIVE
Nov 7, 2022